Date |
Company |
Compound |
Disease |
Type of agreement |
Therapeutic area |
Type of Information |
2017-03-09 |
Dynacure (France) |
chief executive officer, chief operating officer, chief development officer, members of the board of directors
|
|
nomination |
Rare diseases - Genetic diseases |
Nomination |
2017-03-08 |
BergenBio (Norway) Merck&Co (USA - NJ) |
BGB324 and pembrolizumab |
dvanced non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC). |
clinical research |
Cancer - Oncology |
Clinical research agreement |
2017-03-07 |
BeiGene (China) Guangzhou GET Technology Development (China) BeiGene Biologics |
commercial-scale biologics manufacturing facility in Guangzhou |
|
joint-venture |
|
Joint-venture agreement |
2017-03-06 |
Argen-X (Belgium) Staten Biotech |
SIMPLE Antibody™ platform, ARGX-116 |
dyslipidemia |
licensing - development |
Cardiovascular diseases - Metabolic diseases |
Exercise of an option agreement |
2017-03-06 |
Theratechnologies (Canada) TaiMed Biologics (Taiwan) |
ibalizumab |
HIV infection |
marketing - distribution |
Infectious diseases |
Commercialisation agreement |
2017-03-06 |
Servier (France) Vernalis (UK) |
|
|
R&D - research |
Cancer - Oncology |
Research agreement |
2017-03-06 |
Polyphor (Switzerland) |
|
|
nomination |
Infectious diseases |
Nomination |
2017-03-06 |
Amag Pharmaceuticals (USA - MA) |
|
|
nomination |
|
Nomination |
2017-03-06 |
Vertex Pharmaceuticals (USA - MA) Concert Pharmaceuticals (USA - MA) |
CTP-656 (D9-ivacaftor ) deuterated ivacaftor |
cystic fibrosis (CF) |
product acquisition |
Rare diseases - Genetic diseases - Lung diseases |
Product acquisition |
2017-03-02 |
Boehringer Ingelheim (Germany) Vanderbilt University (USA -TN) |
small molecule inhibitors of oncogenic Ras |
|
research - R&D |
Cancer - Oncology |
Research agreement |
2017-03-02 |
Melinta Therapeutics (USA - CT) Menarini (Italy) |
Baxdela® (delafloxacin) |
acute bacterial skin and skin structure infections (ABSSSI), hospital-treated community-acquired bacterial pneumonia (hCABP) |
development - commercialisation |
Infectious diseases |
Development agreement |
2017-03-02 |
Allergopharma (Germany) Merck KGaA (Germany) |
biopharmaceutical production plant |
|
opening of new premises |
|
Opening of new premises |
2017-03-02 |
Bioverativ (USA - MA) |
member of the board of directors |
|
nomination |
Rare diseases - Genetic diseases - Hematological diseases |
Nomination |
2017-03-02 |
Arix Bioscience (UK) Takeda Ventures (USA - CA)) |
|
|
collaboration |
Cancer - Oncology - Gastrointestinal diseases |
Collaboration agreement |
2017-03-01 |
Theradiag (France) |
|
|
nomination |
Technology - Services |
Nomination |
2017-03-01 |
Adaptimmune (UK) |
U.S. headquarters |
|
opening of new premises |
Cancer - Oncology |
Opening of new premises |
2017-02-28 |
Veloxis Pharmaceuticals (Denmark) |
|
|
restructuring |
|
Restructuring |
2017-02-28 |
Crispr Therapeutics (Switzerland - USA - MA) |
|
|
nomination |
|
Nomination |
2017-02-27 |
Argen-X (The Netherlands-Belgium) Shire (UK-USA) |
therapeutic antibodies based on arGEN-X\'s SIMPLE Antibody™ technology |
|
development
|
Rare diseases - Genetic diseases |
Development agreement |
2017-02-27 |
CTI BioPharma - previously known as Cell Therapeutics (USA - WA) |
|
|
nomination |
Cancer - Oncology |
Nomination |